吉西他滨方案治疗复发或难治非霍奇金淋巴瘤42例临床分析

Clinical Analysis of Gemcitabine Program in Treatment of 42 Cases with Recurrent or Intractable Non-Hodgkin Lymphoma

目的评价吉西他滨方案治疗复发或难治非霍奇金淋巴瘤近远期疗效。方法 2011年2月—2015年2月,赤峰学院附属医院肿瘤内科收治复发或难治非霍奇金淋巴瘤78例,采用GEMOX方案治疗复发或难治非霍奇金淋巴瘤42例,纳入观察组,采用NO方案治疗36例,纳入对照组,对比疗效、不良作用反应。结果观察组控制率88.1%高于对照组69.4%,观察组血小板减少分级高于对照组,差异有统计学意义(P<0.05);观察组总有效率88.1%、中位生存时间(OS)24(3.0~65.4)个月、无进展生存期(PFS)8(6.83~8.43)个月,对照组则为61.1%、22(2.0~61.6)个月、7(5.82~8.84)个月,差异无统计学意义(P>0.05)。结论吉西他滨方案治疗复发或难治非霍奇金淋巴瘤近期疗效肯定,无效率低,但可能引起血小板减少;吉西他滨方案适合肿瘤负荷较大、进展风险较高的患者。

Objective To evaluate the long-term and short-term curative effect of gemcitabine program in treatment of recurrent or intractable non-Hodgkin lymphoma. Methods 78 cases of patients with recurrent or intractable non- Hodgkin lymphoma admitted and treated in our hospital from February 2011 to February 2015 were selected and divid- ed into two groups, 42 cases of patients with recurrent or intractable non-Hodgkin lymphoma adopted the GEMOX plan, which was the observation group, and 36 cases of patients with NO plan were selected as the control group, and the curative effect and toxic and side effect reactions were compared. Results The control rate and thrombopenia grade in the observation group were higher than those in the control group （88.1% vs 69.4%）, and the differences had statisti- ca] significance（P〈0.05）, the differences in the total effective rate, OS and PFS between the observation group and the control group had no statistical significance, [88.1%24（3.0-65.4）months, 8（6.83-8.43）months vs 61.1%, 22（2.0- 61.6）months ,7（5.82-8.84）months],（P〉0.05）. Conclusion The curative effect of gemcitabine program in treatment of 42 cases with recurrent or intractable non-Hodgkin lymphoma is positive and may cause the thrombopeny, which is suit- able for the patients with heavy tumor load and high progress risk.